GelMEDIX Email Format
Biotechnology ResearchMassachusetts, United States2-10 Employees
GelMEDIX is a biotechnology company focused on developing regenerative medicines to address vision loss, with its lead program aimed at Geographic Atrophy, the leading cause of blindness in adults over 60. The company utilizes an iPSC-derived retinal pigment epithelial (RPE) cell therapy delivered via an injectable hydrogel scaffold, pursuing sustained visual preservation in preclinical studies while aiming to reduce risks associated with earlier approaches. Based in Cambridge, Massachusetts, GelMEDIX targets the ophthalmology space, seeking to regenerate retinal tissue and protect structures essential for vision. The organization emphasizes advancing regenerative therapies to restore sight through its biomaterials platform and cell-based approach.